↓ Skip to main content

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

Overview of attention for article published in Cancer Immunology, Immunotherapy, February 2008
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

patent
5 patents

Citations

dimensions_citation
203 Dimensions

Readers on

mendeley
127 Mendeley
Title
Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma
Published in
Cancer Immunology, Immunotherapy, February 2008
DOI 10.1007/s00262-008-0491-8
Pubmed ID
Authors

Jaafar Bennouna, Emmanuelle Bompas, Eve Marie Neidhardt, Frédéric Rolland, Irène Philip, Céline Galéa, Samuel Salot, Soraya Saiagh, Marie Audrain, Marie Rimbert, Sylvie Lafaye-de Micheaux, Jérôme Tiollier, Sylvie Négrier

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 127 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Germany 1 <1%
France 1 <1%
Unknown 123 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 24 19%
Student > Bachelor 19 15%
Student > Ph. D. Student 19 15%
Student > Master 17 13%
Student > Doctoral Student 8 6%
Other 12 9%
Unknown 28 22%
Readers by discipline Count As %
Immunology and Microbiology 23 18%
Agricultural and Biological Sciences 23 18%
Biochemistry, Genetics and Molecular Biology 19 15%
Medicine and Dentistry 17 13%
Nursing and Health Professions 6 5%
Other 10 8%
Unknown 29 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 April 2023.
All research outputs
#3,407,363
of 23,510,717 outputs
Outputs from Cancer Immunology, Immunotherapy
#235
of 2,938 outputs
Outputs of similar age
#10,017
of 80,419 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#5
of 29 outputs
Altmetric has tracked 23,510,717 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,938 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 80,419 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.